A5036284552- Medication Adherence and Compliance
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Renal Transplantation Outcomes and Treatments
- Advanced Breast Cancer Therapies
- Lung Cancer Research Studies
- Breast Cancer Treatment Studies
- Blood Pressure and Hypertension Studies
- Cancer Treatment and Pharmacology
- Adenosine and Purinergic Signaling
- Cancer, Lipids, and Metabolism
- Prostate Cancer Treatment and Research
- CAR-T cell therapy research
- Genetic and Kidney Cyst Diseases
- Bipolar Disorder and Treatment
- Cancer-related Molecular Pathways
- HIV/AIDS Research and Interventions
- Cancer survivorship and care
- Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Hematopoietic Stem Cell Transplantation
- Artificial Intelligence in Healthcare and Education
- HER2/EGFR in Cancer Research
- Cancer-related cognitive impairment studies
- Fatty Acid Research and Health
Université Libre de Bruxelles
2022-2024
Institut Jules Bordet
2022-2024
Ablynx (Belgium)
2016
Eonic Systems (Belgium)
2007
<b>Objective</b> To describe characteristics of dosing history in patients prescribed a once day antihypertensive medication. <b>Design</b> Longitudinal database study. <b>Setting</b> Clinical studies archived for 1989-2006. <b>Participants</b> Patients who participated the whose histories were available through electronic monitoring. <b>Main outcome measures</b> Persistence with treatment and execution their drug regimens. <b>Results</b> The contained 4783 hypertension. data came from 21...
In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target rapamycin (mTOR) pathway is associated with progressive enlargement. The drug sirolimus suppresses mTOR signaling.In this 18-month, open-label, randomized, controlled trial, we sought to determine whether halts growth in volume among patients ADPKD. We randomly assigned 100 between ages 18 and 40 years receive either (target dose, 2 mg daily) or standard care. All had an estimated creatinine...
With effective agents available to prevent posttransplantation acute organ rejection, medication adherence becomes a key factor for successful treatment outcomes after renal transplantation. A once-daily, modified-release oral formulation of tacrolimus has been developed simplify dosing and improve adherence.Adherence Measurement in Stable Renal Transplant Patients Following Conversion From Prograft Advagraf is randomized multicenter controlled trial evaluate between once-daily regimen...
We aimed to evaluate the role of prostate-specific membrane antigen (PSMA) PET/CT for response assessment and outcome prediction in patients with metastatic castration-resistant prostate cancer (mCRPC) treated androgen receptor pathway inhibitors (ARPIs), including abiraterone acetate or enzalutamide. <b>Methods:</b> retrospectively analyzed 30 ARPI-treated mCRPC who underwent <sup>68</sup>Ga-PSMA-11 within 8 wk before (baseline) 12 ± 4 after treatment initiation. Total PSMA tumor volume was...
Abstract Chemo-immunotherapy is the first-line standard of care for patients with PD-L1 positive metastatic triple-negative breast cancer (mTNBC). SYNERGY (NCT03616886) a dose-finding phase I and randomized II, open-label trial evaluating if targeting immunosuppressive adenosine pathway can enhance antitumor activity chemo-immunotherapy. The part included 6 untreated locally-advanced or mTNBC to determine safety recommended II dose anti-CD73 antibody oleclumab in combination anti-PD-L1...
Sirolimus has been approved for clinical use in non proliferative and disorders. It inhibits the mammalian target of rapamycin (mTOR) signaling pathway which is also known to regulate ovarian morphology function. Preliminary observational data suggest potential toxicity but this issue not studied randomized controlled trials. We reviewed self-reported occurrence menstrual cycle disturbances appearance cysts post hoc an open label phase II trial conducted at University Hospital Zürich between...
This pilot study was designed to evaluate the feasibility and benefits of electronic adherence monitoring antiretroviral medications in HIV patients who recently started Highly Active Anti Retroviral Therapy (HAART) Francistown, Botswana compare this with self-reporting. Dosing histories were compiled electronically using Micro Electro Mechanical Systems (MEMS) monitors prescribed therapies. Thirty enrolled treatment program monitored over 6 weeks. These all (ARV) naïve. After each visit...
Optimal dosing and duration of adjuvant treatment with PD-1 CTLA-4 immune checkpoint inhibitors have not been established. Prior to their regulatory approval we investigated a low-dose regimen nivolumab or without ipilimumab in sequential dual-cohort phase II clinical trial.
This study reports the short- and mid-term benefits of an eight-session emotion self-regulation group intervention ecologically boosted through daily app-based prompts. The was designed for breast cancer patients in early survivorship period meeting criteria clinical levels psychological symptoms.Patients were randomly assigned to immediate arm (n = 61; received immediately) or delayed 59; 5 months later). Psychological symptoms, including anxiety, depressive emotional distress, fear...
Abstract Background: Metastatic triple-negative breast cancer (mTNBC) is the most aggressive and heterogeneous subtype, with limited therapeutic options. Immune-checkpoint inhibitors (ICI) chemotherapy are approved as first-line therapy in mTNBC for patients PD-L1+tumors. The generation of immunosuppressive extracellular adenosine tumor microenvironment by overexpression ectoenzyme CD73 a mechanism that could impair ICI activity. SYNERGY trial investigates if addition an anti-CD73 monoclonal...
Peptide receptor radionuclide therapy (PRRT) with [177Lu]Lu-DOTA-TATE has emerged as a promising treatment for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Its protocol is currently standardised all patients, resulting in different patient outcomes. This study investigates the variability of and organs-at-risk (kidneys red marrow) dosimetric parameters across cycles patients pancreatic intestinal NETs. Data from 37 enrolled prospective phase II (LuMEn) were analysed. Treatment...
<h3>Introduction/Background</h3> There is no evidence that resection margins after breast conserving surgery (BCS), defined as 'no ink on tumor' can be applied to patients receiving neoadjuvant systemic treatment (NST). The study aim was evaluate the impact of distance loco-regional recurrence (LRR) and survival treated by BCS following NST. <h3>Methodology</h3> This a retrospective including who underwent NST followed BCS. LRR-free (LRRS), disease-free (DFS) overall (OS) assessed according...
Overexpression of CD73 in breast cancer is associated with immunosuppressive, pro-angiogenic tumor microenvironment and poor patient clinical outcomes. Anti-CD73 antibodies are being investigated combination immune checkpoint inhibitors trials. Here, we the prognostic value soluble form (sCD73) patients advanced triple negative (TNBC) treated first-line durvalumab chemotherapy, or without anti-CD73 antibody oleclumab randomized, phase II SYNERGY trial (NCT03616886). sCD73 levels were...